Manifold Bio, a new startup founded by one of Boston’s most prolific biotech entrepreneurs, has raised $40 million to develop a technology that could make testing cancer drugs more efficient. The company is designing a system for “barcoding” protein therapies — giving them a unique label so that dozens or hundreds of them can be tested at the same time to see which are best at targeting tumors.
The startup was originally founded in 2019 by George Church, a professor at Harvard Medical School, and two of his former graduate students, Gleb Kuznetsov and Pierce Ogden, who are now chief executive and chief scientific officer of the company.
Church has founded more than 20 biotech companies, including the CRISPR gene editing firm Editas Medicine. His startups are often based on cutting-edge genetic technologies. For instance, eGenesis, founded in 2015, is creating gene-edited pigs so that their organs can be transplanted in humans. And Colossal Biosciences, founded last year, is trying to resurrect the woolly mammoth.
Create a display name to comment
This name will appear with your comment
